AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04871412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theracurmin 2X
Description: 1.2g twice daily after the peri-operative period. including during adjuvant chemotherapy and radiation
Study NCT04871412 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green Tea Extract
Description: 700 mg twice daily after the peri-operative period. Will not be given during adjuvant radiation or chemotherapy treatments.
Study NCT04871412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition Recommendations
Description: Based on the Mediterranean diet and lower glycemic index foods
Study NCT06779227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital family transitional nursing intervention
Description: The intervention group received a transitional care intervention mainly focused on the transitional care model (TCM).
Study NCT06694454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine (IV), 1,250 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study NCT06694454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Pemetrexed (IV), 500 mg/m\^2, administered on day 4 of every cycle (1 cycle=21 days), for a maximum (total) of 3 cycles.
Study NCT06630169 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Cryopreserved AURN001
Description: Corneal Endothelial Cells and Y27632
Study NCT06696040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive mobilization using a device
Description: The protocol consists of three moments: initial assessment, use of the device, and final assessment.~In the initial assessment, participants will be positioned supine on a stretcher, where the muscle tone of the lower limb(s) will be tested using the Modified Ashworth Scale. After the physical test with the Modified Ashworth Scale, the TUG test will be carried out, and, finally, gait assessment with the BAIOBIT Inertial Meter with Accelerometer and Gyroscope.~At the end of the initial assessment, the Autofisio500 device will be used. To do this, the participant will be positioned again and comfortably supine on the stretcher, and the previously tested lower limb will be attached to the device for movement, between the knee and ankle joints, for 30 minutes, at maximum speed (11 RPM).~For the final assessment, the Modified Ashowrth Scale, TUG and gait assessment with the Inertial Meter with Accelerometer and BAIOBIT Gyroscope will be applied again.
Study NCT06778980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The chin tuck posture
Description: A chin tuck is a posture correction technique where the individual gently tucks their chin towards their chest while keeping the rest of the body straight. This movement helps align the head and neck, reducing forward head posture and improving spinal alignment. After performing the unguided exercises, the patients will be taught the chin tuck position. From this point onward, they will be instructed to maintain the chin tuck position while performing the exercises using both external and internal focus strategies.
Study NCT06632002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSF1
Description: 220 mL
Study NCT06632002 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DSF2
Description: 220 mL
Study NCT06779240 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaires
Description: The clinical protocols at our institute involve the regular and continuous evaluation of the quality of life in patients undergoing treatment and monitoring for scoliosis and other vertebral deformities. To this end, the SRS-22 (Scoliosis Research Society) questionnaire and the ODI (Oswestry Disability Index) questionnaire are employed, along with other measures such as the COMI (Core Outcome Measure Index) and ISYQoL (Italian Spine Youth Quality of Life) and administrated to every patients
Study NCT05647434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sustained inflations
Description: Sustained inflation will be applied at a pressure of 30 cmH2O and will be held for a period of 30 secs. After each SI the standard ventilatory settings will be resumed with a PEEP setting of 8 cmH2O to prevent lung derecruitment. Lung recruitment will be stopped immediately if mean arterial pressure and/or heart rate change by at least 25% from baseline values.
Study NCT06778707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Oblique Intercostal Block
Description: In group E, a needle will be used to pierce the skin, subcutaneous tissue then external oblique muscle to hydrodissect the fascial plane between external oblique muscle and intercostal muscles with 25 ml bupivacaine 0.25 % and 4 mg dexamethasone added to it.
Study NCT06778707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcostal Transversus Abdominis Plane Block
Description: In group T, a needle will be used to pierce the skin, subcutaneous tissue then rectus muscle and 25 ml of 0.25 % bupivacaine with 4 mg dexamethasone will be injected between rectus muscle and transversus abdominis muscle.
Study NCT06779513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiohraphy
Description: Transthoracal echocardiography for diastolic function assessment
Study NCT06779370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Silicate
Description: Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium silicate-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
Study NCT06779370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium hydroxide-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
Study NCT06779305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical application of Calcanail®
Description: The procedure involves making small incisions to insert a specialized nail into the bone to realign and stabilize the fracture. This approach minimizes damage to surrounding tissues, reduces the risk of wound complications, and allows for quicker recovery compared to traditional open surgery. after surgery, the patient will benefit from an immobilisation with a plaster boot without support for 3 weeks, followed by immobilisation with a removable walking boot for 3 weeks with partial support depending on the patient's pain.
Study NCT06779305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immobilisation by cast boot
Description: The patient will be immobilised in a plaster cast without support for 3 weeks, followed by immobilisation in a removable walking boot for 3 weeks with partial support depending on the pain.
Study NCT04871412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Recommendations
Description: 150 minutes moderate intensity aerobic exercise per week plus the addition of a resistance exercise program on 2 of those days
Study NCT04871412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Recommendations
Description: Activities with the intention of actively improving the participant's mental and emotional health
Study NCT06364813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMPANION eHealth Program
Description: COMPANION consists of online, self-paced educational modules with information on a range of topics such as providing medical care, applying for financial aid and home aid, working on the relationship with the care recipient, dealing with mental health issues, and learning life skills.
Study NCT06632002 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC)
Description: Standard of care
Study NCT06632002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Standard of care
Study NCT06629779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06821497
Description: Oral continuous
Study NCT06629779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral continuous
Study NCT06352619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative SBP Control
Description: No or minimal treatment; if there is a need to treat a patient with a very-high (>180 mmHg) baseline SBP, then the SBP reduction is 5-10mmHg or a target is 175-180 mmHg
Study NCT06352619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate SBP Control
Description: If the patient has a very high (>180 mmHg) or moderate high (160-180 mmHg) baseline SBP, SBP reduction is 10-20mmHg or a target of160±5 mmHg, which is higher; patients with low-high (150-160 mmHg) baseline SBP will not be treated
Study NCT06352619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive SBP Control
Description: SBP reduction by 30-50mmHg or a target of 140±5 mmHg, which is higher
Study NCT06088758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP) of steatotic liver
Description: Steatotic liver grafts that are selected will be run on NMP to assess quality of graft and determine whether it meets criteria for transplantation
Study NCT06648135 — intervention group
Intervention type: PROCEDURE
Intervention: Immediate implants with bone grafts
Description: Immediate implants with bone grafts
Study NCT06648135 — intervention group
Intervention type: PROCEDURE
Intervention: Immediate implant placed without bone grafts or any grafting substitutes in the labial gap
Description: Immediate implant placed without bone grafts or any grafting substitutes in the labial gap
Study NCT05148988 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EchoPIV
Description: All patients will undergo an echoPIV measurement 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair. These measurements will take place at the Vascular Center of Rijnstate Hospital. A venous cannula will be inserted to enable contrast administration. Ultrasound data will be collected at the caudal renal artery, infrarenal neck, aneurysm sac and both iliac arteries.
Study NCT05148988 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 4D flow MRI
Description: A 4D phase-contrast magnetic resonance imaging (4D flow MRI) scan of the abdominal aorta will be obtained 6 to 8 weeks before and 6 to 8 weeks after endovascular aneurysm repair.
Study NCT05321992 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eCHEC program
Description: The eCHEC program is the enhanced Community-based Health Education and Communication (CHEC) model to prevent O. viverrini in an effort to decrease cholangiocarcinoma (CCA) in Khon Kaen, Thailand
Study NCT06268015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: 75 mg IV every 6 weeks for up to 4 doses
Study NCT06268015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: 240 mg IV every 2 weeks
Study NCT06268015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV every 2 weeks
Study NCT06268015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 IV every 2 weeks
Study NCT06629779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral continuous
Study NCT06629779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Oral continuous
Study NCT06690658 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: incorporating robotic system for upper body physical training of people with lower limb orthopedic condition
Description: A training session begins with the robot introducing itself, and the participant sits in front of the robot. The robot will demonstrate upper body exercises and will provide verbal instructions and feedback (e.g, number of successful repetitions, motivational). At the beginning of the session, the participant will be asked to follow the robot's demonstration and simultaneously perform the exercise. At the end of each exercise, the robot will provide feedback. If the participant successfully performed ten repetitions of the required exercise in the demonstration time allocated, positive feedback will be provided. Resistance (strengthening) exercises for the upper body include lifting weights, working with resistance bands in different directions involving the upper extremity and trunk. Flexibility exercises include upper extremity and trunk stretching.
Study NCT06686849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-touch: texting
Description: Text message: The patients' primary caregiver will be sent up to three text messages spaced one week apart, starting at one week post no-show. The message will identify the child by the first name and give information about the missed visit (date, time, clinic location) and how to reschedule (by clinic-specific phone number, and/or directing the patient to myatriumhealth.org). If a patient has a newly scheduled well-child visit on file prior to all three text messages being sent, messages will be stopped.
Study NCT06686849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-touch: Community health worker outreach
Description: Community health worker (CHW) outreach: Within approximately one week of patient enrollment and randomization to the high-touch intervention arm, the community health worker will call the primary phone number in the patient's record. Up to three phone call attempts will be made and logged for this number, then a fourth and final attempt will be made to reach the secondary contact phone number in the patient's health record. If the caregiver is successfully reached, the CHW intervention will be limited to one phone call in which the CHW will assess reason(s) why the patient missed the appointment, will screen for social and other needs, and will assist in rescheduling the missed appointment and addressing potential barriers to attendance.
Study NCT06630611 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NMA-LD regimen
Description: The use of the NMA-LD regimen (cyclophosphamide and fludarabine) prior to cell administration is expected to lead to myelosuppression in all patients.
Study NCT06630611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NMA-LD regimen
Description: The use of the NMA-LD regimen (cyclophosphamide and fludarabine) prior to cell administration is expected to lead to myelosuppression in all patients.
Study NCT06630611 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion
Description: On Day 0 (at least 24h after the last dose of fludarabine) patients will be hospitalized in a dedicated unit. Autologous TIL infusion will be administered intravenously.
Study NCT06630611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion
Description: On Day 0 (at least 24h after the last dose of fludarabine) patients will be hospitalized in a dedicated unit. Autologous TIL infusion will be administered intravenously.
Study NCT06630611 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose IL-2
Description: Only for patients in Arm A.~IL-2 begins between 3 and 24 hours after the completion of the TIL infusion and is given as a bolus administration every eight hours (minimum interval) to 24 hours (maximum interval) with a maximum of six doses from the beginning of each administration.
Study NCT06630611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2 analog
Description: Only for patients in Arm B~ANV419 will be administered between 3 and 24 hours after the completion of the TIL infusion with a slow IV infusion over 15-30 minutes + 5 minutes once, at 243µg/kg.
Study NCT04946838 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DS5 electrical stimulator
Description: TENS
Study NCT04946838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS5 electrical stimulator
Description: TENS
Study NCT06268015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400 mg/m2 IV bolus + 2,400 mg/m2 IV (over 46 hours) every 2 weeks
Study NCT06268015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg IV every 2 weeks
Study NCT05807139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT06056336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab 200 mg q21d up to 1 year. Nad-paclitaxel 260 mg/m2, IV., every 3 weeks, 2-3 cycles. Carboplatin area under the curve = 5, IV., every 3 weeks, 2 cycles.
Study NCT04659174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanomeline and Trospium Chloride Capsules
Description: Oral xanomeline 50 mg/trospium chloride 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium chloride 20 mg BID on days 3-7. The dosage is increased to xanomeline 125 mg/trospium chloride 30 mg BID on days 8-364 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium chloride 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium chloride 30 mg will have the option to return to xanomeline 100 mg/ trospium chloride 20 mg depending on clinical response and tolerability. Re-escalation to 125/30 BID or re-titration in cases in which the subject has been off KarXT for a longer period of time (at least a week) is allowed and will require a discussion between the principal investigator and the medical monitor.
Study NCT05071872 — intervention group
Intervention type: DEVICE
Intervention: Atherectomy/Thrombectomy
Description: Percutaneous transluminal removal of thrombotic occlusion in arteriovenous graft
Study NCT06313502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75gm HDAA
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 75gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 120 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.
Study NCT06313502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100gm HDAA
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 100gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 180 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.
Study NCT06313502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125gm HDAA
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 125gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 240 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.
Study NCT06243003 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HA-WBRT plus SBRT
Description: hippocampal-avoidance whole brain radiotherapy (WBRT) followed by stereotactic body radiotherapy (SBRT)
Study NCT05259137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intralesional enalaprilat injection
Description: 1.0 mL of 1.25 mg/mL enalaprilat
Study NCT00754949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Azithromycin and 0.1% Dexamethasone
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Study NCT00754949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Azithromycin
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Study NCT00754949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Dexamethasone
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.